US20060271170A1 - Stent with flexible sections in high strain regions - Google Patents
Stent with flexible sections in high strain regions Download PDFInfo
- Publication number
- US20060271170A1 US20060271170A1 US11/141,834 US14183405A US2006271170A1 US 20060271170 A1 US20060271170 A1 US 20060271170A1 US 14183405 A US14183405 A US 14183405A US 2006271170 A1 US2006271170 A1 US 2006271170A1
- Authority
- US
- United States
- Prior art keywords
- stent
- high strain
- strain region
- section
- flexible section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920000642 polymer Polymers 0.000 claims description 45
- 230000007935 neutral effect Effects 0.000 claims description 37
- 238000005452 bending Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 230000007423 decrease Effects 0.000 claims description 11
- 238000000151 deposition Methods 0.000 claims description 11
- 239000011877 solvent mixture Substances 0.000 claims description 5
- 238000003698 laser cutting Methods 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 3
- 230000009477 glass transition Effects 0.000 claims description 3
- -1 poly(N-acetylglucosamine) Polymers 0.000 description 31
- 239000000463 material Substances 0.000 description 28
- 238000002788 crimping Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- 230000008021 deposition Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000005336 cracking Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- UHKPXKGJFOKCGG-UHFFFAOYSA-N 2-methylprop-1-ene;styrene Chemical compound CC(C)=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 UHKPXKGJFOKCGG-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229920006370 Kynar Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 229920001077 Poly(N-acetyl glucosamine) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 229920006220 SOLEF 21508 PVDF Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229920006212 co-poly(ether-esters) Polymers 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 238000004924 electrostatic deposition Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229920006213 ethylene-alphaolefin copolymer Polymers 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 1
- 229920000071 poly(4-hydroxybutyrate) Polymers 0.000 description 1
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 1
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920006211 poly(glycolic acid-co-trimethylene carbonate) Polymers 0.000 description 1
- 229920006210 poly(glycolide-co-caprolactone) Polymers 0.000 description 1
- 229920001072 poly(l-lactide-co-caprolactone) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920006219 poly(vinylidene fluoride-co-hexafluoropropene) Polymers 0.000 description 1
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920006216 polyvinyl aromatic Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920006215 polyvinyl ketone Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920006214 polyvinylidene halide Polymers 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000010107 reaction injection moulding Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006126 semicrystalline polymer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 238000009757 thermoplastic moulding Methods 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91575—Adjacent bands being connected to each other connected peak to trough
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0029—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in bending or flexure capacity
Definitions
- This invention relates to implantable medical devices, such as stents.
- the invention relates to stents having structural elements with flexible or deformable sections that increase the crack resistance of the stent during use.
- This invention relates to radially expandable endoprostheses, which are adapted to be implanted in a bodily lumen.
- An “endoprosthesis” corresponds to an artificial device that is placed inside the body.
- a “lumen” refers to a cavity of a tubular organ such as a blood vessel.
- a stent is an example of such an endoprosthesis.
- Stents are generally cylindrically shaped devices, which function to hold open and sometimes expand a segment of a blood vessel or other anatomical lumen such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in blood vessels.
- Stepnosis refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce body vessels and prevent restenosis following angioplasty in the vascular system.
- Restenosis refers to the reoccurrence of stenosis in a blood vessel or heart valve after it has been treated (as by balloon angioplasty, stenting, or valvuloplasty) with apparent success.
- the treatment of a diseased site or lesion with a stent involves both delivery and deployment of the stent.
- Delivery refers to introducing and transporting the stent through a bodily lumen to a region, such as a lesion, in a vessel that requires treatment.
- Delivery corresponds to the expanding of the stent within the lumen at the treatment region. Delivery and deployment of a stent are accomplished by positioning the stent about one end of a catheter, inserting the end of the catheter through the skin into a bodily lumen, advancing the catheter in the bodily lumen to a desired treatment location, expanding the stent at the treatment location, and removing the catheter from the lumen.
- the stent In the case of a balloon expandable stent, the stent is mounted about a balloon disposed on the catheter. Mounting the stent typically involves compressing or crimping the stent onto the balloon. The stent is then expanded by inflating the balloon. The balloon may then be deflated and the catheter withdrawn. In the case of a self-expanding stent, the stent may be secured to the catheter via a retractable sheath or a sock. When the stent is in a desired bodily location, the sheath may be withdrawn which allows the stent to self-expand.
- the stent must be able to satisfy a number of mechanical requirements.
- the stent must be capable of withstanding the structural loads, namely radial compressive forces, imposed on the stent as it supports the walls of a vessel. Therefore, a stent must possess adequate radial strength.
- Radial strength which is the ability of a stent to resist radial compressive forces, is due to strength and rigidity around a circumferential direction of the stent. Radial strength and rigidity, therefore, may be also be described as, hoop or circumferential strength and rigidity.
- the stent should also be longitudinally flexible to allow it to be maneuvered through a tortuous vascular path and to enable it to conform to a deployment site that may not be linear or may be subject to flexure.
- the material from which the stent is constructed must allow the stent to undergo expansion. Once expanded, the stent must maintain its size and shape throughout its service life despite the various forces that may come to bear on it, including the cyclic loading induced by the beating heart.
- the stent must be biocompatible so as not to trigger any adverse vascular responses.
- the structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements or struts.
- the scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape.
- the scaffolding is designed so that the stent can be radially contracted (to allowed crimping) and radially expanded (to allow deployment).
- a conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other. Such movement typically results in substantial deformation of localized portions of the stent's structure.
- Stents have been made of many materials such as metals and polymers, including biodegradable polymeric materials.
- An advantage of stents fabricated from polymers is that they can be designed to have greater flexibility than metal stents.
- a potential problem with polymeric stents is that their struts may be susceptible to cracking during crimping and expansion especially for brittle polymers. The localized portions of the stent pattern subjected to substantial deformation tend to be the most vulnerable to failure.
- the present invention is directed to embodiments of a stent having structural elements that may include a flexible or deformable section embedded within a high strain region of a structural element.
- the flexible section may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region.
- the flexible section may have a greater flexibility than a majority of the structural element outside of the flexible section.
- the high strain region may have a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use.
- the section may be selectively positioned to increase resistance to strain in the high strain region to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
- a further aspect of the invention is directed to embodiments of a method of forming a stent.
- the method may include forming a cavity within a high strain region of a structural element.
- the cavity may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region.
- the high strain region may include a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use.
- the method may further include forming a flexible section within all or substantially all of the cavity.
- the flexible section may have a greater flexibility than a majority of the structural element outside of the flexible section.
- the section may be selectively positioned to reduce an amount of strain in the high strain region to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
- FIG. 1A depicts a stent.
- FIG. 1B depicts a three-dimensional view of a portion of a stent.
- FIG. 2A depicts a side view of a portion of a stent.
- FIG. 2B depicts a side view of an expanded portion of a stent.
- FIG. 2C depicts a side view of a compressed portion of a stent.
- FIG. 3 depicts an expanded view of curved portion of a stent.
- FIG. 4 depicts a side view of a portion of a stent.
- FIG. 5 depicts a side view of a portion of a stent.
- FIG. 6 depicts a side view of a portion of a stent with a flexible section.
- FIG. 7 depicts a side view of an expanded portion of a stent with a flexible section.
- FIG. 8 depicts a side view of a compressed portion of a stent with a flexible section.
- FIG. 9 depicts a side view of a portion of a stent with multiple flexible sections.
- FIG. 10 depicts a three-dimensional side view of a portion of a stent with a cavity.
- the “glass transition temperature,” T g is the temperature at which the amorphous domains of a polymer change from a brittle vitreous state to a solid deformable or ductile state at atmospheric pressure.
- the T g corresponds to the temperature where the onset of segmental motion in the chains of the polymer occurs.
- T g of a given polymer can be dependent on the heating rate and can be influenced by the thermal history of the polymer. Furthermore, the chemical structure of the polymer heavily influences the glass transition by affecting mobility.
- Stress refers to force per unit area, as in the force acting through a small area within a plane. Stress can be divided into components, normal and parallel to the plane, called normal stress and shear stress, respectively. Tensile stress, for example, is a normal component of stress applied that leads to expansion (increase in length). In addition, compressive stress is a normal component of stress applied to materials resulting in their compaction (decrease in length). Stress may result in deformation of a material, which refers to change in length. “Expansion” or “compression” may be defined as the increase or decrease in length of a sample of material when the sample is subjected to stress.
- Stress refers to the amount of expansion or compression that occurs in a material at a given stress or load. Strain may be expressed as a fraction or percentage of the original length, i.e., the change in length divided by the original length. Strain, therefore, is positive for expansion and negative for compression.
- a property of a material that quantifies a degree of strain with applied stress is the modulus.
- “Modulus” may be defined as the ratio of a component of stress or force per unit area applied to a material divided by the strain along an axis of applied force that results from the applied force.
- a material has both a tensile and a compressive modulus.
- a material with a relatively high modulus tends to be stiff or rigid.
- a material with a relatively low modulus tends to be flexible.
- the modulus of a material depends on the molecular composition and structure, temperature of the material, and the strain rate or rate of deformation. For example, below its T g , a polymer tends to be brittle with a high modulus. As the temperature of a polymer is increased from below to above its T g , its modulus decreases.
- the “ultimate strength” or “strength” of a material refers to the maximum stress that a material will withstand prior to fracture.
- a material may have both a tensile and a compressive strength. The ultimate strength may be calculated from the maximum load applied during a test divided by the original cross-sectional area.
- elastic deformation refers to deformation of an object in which the applied stress is small enough so that the object moves towards its original dimensions or essentially its original dimensions once the stress is released.
- an elastically deformed polymer material may be prevented from returning to an undeformed state if the material is below the T g of the polymer. Below T g , energy barriers may inhibit or prevent molecular movement that allows deformation or bulk relaxation.
- Elastic limit refers to the maximum stress that a material will withstand without permanent deformation.
- Yield point is the stress at the elastic limit and the “ultimate strain” is the strain at the elastic limit.
- plastic deformation refers to permanent deformation that occurs in a material under stress after elastic limits have been exceeded.
- Neutral axis refers to a line or plane in a structural member subjected to a stress at which the strain is zero.
- a beam in flexure due to stress e.g., at a top face
- the neutral axis lies between the two sides at a location or locations of zero strain.
- the neutral axis may correspond to a surface.
- the neutral axis is at the geometric centroid (center of mass) of the beam.
- the neutral axis for a curved beam does not coincide with the centroidal axis.
- the strain increases in either direction away from the neutral axis.
- the length and strain of material elements parallel to the centroidal axis depend on both the distance of a material element from that axis and the radius of curvature of the curved beam.
- polymers can be biostable, bioabsorbable, biodegradable, or bioerodable.
- Biostable refers to polymers that are not biodegradable.
- biodegradable, bioabsorbable, and bioerodable, as well as degraded, eroded, and absorbed are used interchangeably and refer to polymers that are capable of being completely eroded or absorbed when exposed to bodily fluids such as blood and can be gradually resorbed, absorbed and/or eliminated by the body.
- a stent made from a biodegradable polymer is intended to remain in the body for a duration of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. After the process of degradation, erosion, absorption, and/or resorption has been completed, no portion of the biodegradable stent, or a biodegradable portion of the stent will remain. In some embodiments, very negligible traces or residue may be left behind. The duration is typically in the range of six to eighteen months.
- a medicated stent may be fabricated by coating the surface of a stent with a polymeric carrier.
- the coating may include a bioactive agent.
- a “bioactive agent” is a moiety that is mixed, blended, bonded or linked to a polymer coating, or to a polymer from which a stent is made, and provides a therapeutic effect, a prophylactic effect, both a therapeutic and a prophylactic effect, or other biologically active effect upon release from the stent.
- polymers that may be used to fabricate embodiments of implantable medical devices disclosed herein include, but are not limited to, poly(N-acetylglucosamine) (Chitin), Chitosan, poly(3-hydroxyvalerate), poly(lactide-co-glycolide), poly(3-hydroxybutyrate), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), poly(caprolactone), poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(trimethylene carbonate), polyester amide, poly(N
- PEO/PLA polyphosphazenes
- biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid
- polyurethanes silicones
- polyesters polyolefins, polyisobutylene and ethylene-alphaolefin copolymers
- acrylic polymers and copolymers other than polyacrylates vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon 66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides,
- polymers that may be especially well suited for use in fabricating embodiments of implantable medical devices disclosed herein include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(butyl methacrylate), poly(vinylidene fluoride-co-hexafluoropropene) (e.g., SOLEF 21508, available from Solvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride (otherwise known as KYNAR, available from ATOFINA Chemicals, Philadelphia, Pa.), ethylene-vinyl acetate copolymers, poly(vinyl acetate), styrene-isobutylene-styrene triblock copolymers, and polyethylene glycol.
- EVAL ethylene vinyl alcohol copolymer
- poly(butyl methacrylate) poly(vinylidene fluoride-co-hexafluoropropene)
- implantable medical device is intended to include, but is not limited to, balloon-expandable stents, self-expandable stents, stent-grafts, and vascular grafts.
- implantable medical devices such as stents
- a stent is composed of a pattern or network of circumferential and longitudinally extending interconnecting structural elements or struts.
- the struts are arranged in patterns, which are designed to contact the lumen walls of a vessel and to maintain vascular patency.
- a myriad of strut patterns are known in the art for achieving particular design goals.
- a few of the more important design characteristics of stents are radial or hoop strength, expansion ratio or coverage area, and longitudinal flexibility.
- Polymer tubes used for fabricating stents may be formed by various methods. These include, but are not limited to extrusion or injection molding. Conventionally extruded tubes tend to possess no or substantially no radial orientation or, equivalently, polymer chain alignment in the circumferential direction.
- a tube used for fabricating a stent may be cylindrical or substantially cylindrical in shape.
- the diameter of the polymer tube prior to fabrication of an implantable medical device may be between about 0.2 mm and about 10 mm, or more narrowly, between about 1 mm and about 3 mm.
- the scaffolding of conventional stents is designed so that the stent can be radially compressed (to allowed crimping) and radially expanded (to allow deployment).
- a conventional stent expands and contracts through movement of individual structural elements of a pattern with respect to each other.
- Medical devices are typically subjected to stress during use, both before and during treatment.
- “Use” includes manufacturing, assembling (e.g., crimping a stent on a balloon), delivery of a stent through a bodily lumen to a treatment site, and deployment of a stent at a treatment site.
- the scaffolding or substrate experiences stress that results in deformation or strain in the scaffolding.
- the scaffolding of a stent can be exposed to stress caused by the radial expansion of the stent body.
- the scaffolding may be exposed to stress when it is mounted on a catheter from crimping or compression of the stent.
- a stent can be exposed to stress from the flexure of the stent body as it passes through tortuous pathways of a vessel.
- a stent is exposed to stress arising from changes in shape of a vessel induced by the beating of the heart.
- selected regions of a stent may be subjected to relatively high stress and strain when the device is under an applied stress during use.
- regions may have different mechanical requirements than regions that experience relatively low stress and strain.
- the stress and the strain in a stent are not uniformly distributed throughout its structure. Some regions may experience no or substantially no stress and strain, while other portions may experience relatively high stress and strain. As indicated above, certain localized portions of the stent's structure undergo substantial deformation. It is these regions that are the most susceptible to fracture and cracking. The susceptibility to cracking may be reduced by making such regions more resistant to strain.
- polymers used for stent scaffoldings are relatively brittle or inelastic at biological conditions. This is particularly true for polymers with a T g above a body temperature. In this case, the polymer in the stent never reaches its T g , and therefore, the polymer remains relatively inelastic while in the body.
- Polymers, in general, and many polymers used in scaffoldings for devices tend to have a relatively high degree of inelasticity, and, hence have relatively low strength compared to a metal. Polymers can have an ultimate strain as low as 5% of plastic strain. In general, the ultimate strain for a polymer is highly dependent on material properties including percent crystallinity, orientation of polymer chains, and molecular weight. Therefore, polymer-based scaffoldings are highly susceptible to fracture at regions of a medical device subjected to relatively high stress and strain.
- regions of a device may be relatively stiff or inelastic (high modulus) and strong. Such regions may experience relatively low stress and strain during use, but act as support members that resist radial compressive forces imposed on a deployed stent. Additionally, as discussed above, longitudinal flexibility in a stent facilitates delivery of the stent to a treatment location. Therefore, it is desirable to have a stent that is resistant to cracking in localized regions of high deformation, sufficiently rigid to maintain the structural integrity of the sent, and longitudinally flexible during delivery.
- FIG. 1A illustrates a three-dimensional view of a conventional stent 10 with a typical stent pattern.
- the stent may have a pattern that includes a number of interconnecting elements or struts 15 . Variations of the structure of such patterns are virtually unlimited.
- the geometry or shape of stents vary throughout their structure.
- a pattern may include portions of struts that are straight or relatively straight, an example being a section 17 .
- patterns may include struts that include curved or bent portions as in a section 20 . Patterns may also include intersections of struts with curved or bent portions as in sections 25 and 30 .
- struts 15 of stent 10 include luminal faces 35 , abluminal faces 40 , and side-wall faces 45 .
- FIG. 1B depicts a portion 54 of a strut depicting a latitudinal axis 50 and a longitudinal axis 55 along a straight section of portion 54 .
- Portion 54 has an abluminal or luminal face 59 and a sidewall face 57 .
- a longitudinal axis 51 on a curved section of a strut may be defined as a tangent to a curvature at a location on the curved section.
- a corresponding latitudinal axis 56 is perpendicular to longitudinal axis 51 .
- a latitudinal cross-section may include any number of faces or be a curved surface.
- a pattern of a stent such as that pictured in FIG. 1A , may be formed from a tube by laser cutting the pattern of struts in the tube.
- the stent may also be formed by laser cutting a polymeric sheet, rolling the pattern into the shape of the cylindrical stent, and providing a longitudinal weld to form the stent.
- Other methods of forming stents are well known and include chemically etching a polymeric sheet and rolling and then welding it to form the stent.
- the stent may be formed by injection molding of a thermoplastic or reaction injection molding of a thermoset polymeric material.
- crimping and expansion of a stent with a typical pattern result in localized regions of the pattern having high deformation or strain that are susceptible to failure.
- the stent pattern depicted in FIG. 1A may be used to illustrate such localized regions. Some portions of a stent pattern may have no or relatively no strain, while others may have relatively high strain.
- Straight or substantially straight sections of struts such as section 17 of stent 10 in FIG. 1A experience no or relatively no strain. These sections, however, do act as support members that maintain the structural integrity of the stent.
- sections 20 , 25 , and 30 may experience relatively high strain when the stent is expanded or crimped.
- FIGS. 2 A-C depict partial planar side views of luminal or abluminal surfaces of a portion 60 from a stent in a relaxed state (neither expanded or compressed) that includes straight sections 65 and a curved section 70 with an angle 85 .
- a stent undergoes radial expansion, portions of struts bend resulting in an increase of angle 85 between straight sections 65 , as shown in FIG. 2B .
- a bending plane of portion 60 corresponds to the plane through which sections 65 sweep through as they bend.
- the bending plane may correspond to the plane of the sheet of paper.
- the abluminal and luminal surfaces may be substantially parallel to the bending plane of the bending portions of structural elements such as portion 60 .
- FIGS. 2 B-C depict portion 60 in a plane of bending. Radial expansion of a stent causes substantially no strain in straight sections 65 . However, the bending of section 60 causes relatively high stress and strain in curved section 70 . As illustrated in FIG. 2B , when a stent is expanded a concave portion 75 of curved section 70 experiences relatively high tensile stress and strain and a convex portion 80 of curved section 70 experiences relatively high compressive stress and strain. As shown in FIG. 2C , when a stent is crimped, angle 85 decreases and concave portion 75 experiences relatively high compressive strain and convex portion 80 experiences relatively high tensile strain.
- FIG. 3 depicts an expanded view of curved section 70 with a neutral axis 90 indicated.
- the strain along the neutral axis is zero.
- the neutral axis may be a surface perpendicular to a plane of bending (i.e., perpendicular to the plane of the sheet of paper).
- a centroidal axis 95 of a curved section of a strut, such as section 70 does not coincide with the neutral axis. Therefore, in a small, narrow region of curved section 70 along neutral axis 90 , there is zero or relatively low strain.
- the strain in a structural element or beam increases with distance from the neutral axis. Therefore, the strain in section 70 depends on distance from the neutral axis 90 and the change in curvature from an equilibrium or unstressed curvature of section 70 . For instance, a bending moment 100 that tends to straighten section 70 , as in FIG. 2B , results in strain above and below the neutral axis.
- the magnitude of the strain as a function of the distance from the neutral axis at a plane 105 is illustrated by arrows 110 and 115 . Above neutral axis 90 , the strut is in compression with a compressive strain that increases with distance from neutral axis 90 , as shown by arrows 110 .
- the maximum tensile and compressive strain occur the edges of a structural element. In FIG. 3 , the maximum tensile and compressive strain along plane 105 is at 120 and 125 , respectively.
- the magnitude of the strain in a bending element or beam varies along the longitudinal axis of the element.
- the maximum strain tends to occur at a center of symmetry of the bending element.
- the strain tends to decrease along the longitudinal axis with distance going away from the center of symmetry of the bend. For example, if plane 105 is a center of symmetry of bending, the strain decreases with distance away from plane 105 along a longitudinal axis of section 70 at a fixed distance from neutral axis 90 .
- FIG. 4 depicts a partial planar side view of a portion 150 from a stent in an unstressed state that includes curved section 155 , straight sections 160 at an angle 165 , and straight section 170 .
- Radial expansion of the stent increases angle 165 and crimping decreases angle 165 .
- the stress and strain in straight sections 160 and 170 is relatively small.
- section 155 When a stent is expanded, section 155 has relatively high tensile stress and strain above a neutral axis 175 and relatively high compressive stress and strain below neutral axis 175 .
- section 155 has relatively high tensile stress and strain below neutral axis 175 and relatively high compressive stress and strain above neutral axis 175 .
- FIG. 5 depicts a partial planar side view of a portion 200 from a stent in an unstressed state that includes a curved section 205 , straight sections 225 , 230 , and 240 .
- Straight sections 225 and 230 are at an angle 235 and straight sections 230 and 240 are at an angle 250 .
- Radial expansion of the stent increases angles 235 and 250 and crimping decreases angles 235 and 250 .
- the stress and strain in straight sections 225 , 230 , and 240 is relatively small.
- section 205 When a stent is expanded, section 205 has relatively high tensile stress and strain above a neutral axis 260 and relatively high compressive stress and strain below neutral axis 260 .
- section 205 has relatively high tensile stress and strain below neutral axis 260 and relatively high compressive stress and strain above neutral axis 260 .
- the description and analysis relating to stress and strain distribution in a medical device is not limited to the structures in FIGS. 2 A-C, 3 , and 4 . Analysis of strain distribution in a device, or generally any structure, subjected to applied stress may be performed for a device or structure of virtually any geometry
- high strain regions of polymeric stents such as section 70 in FIGS. 2 A-C, section 155 in FIG. 3 , and section 205 in FIG. 4 , may be susceptible to cracking during crimping or expansion of a stent.
- the resistance to strain of the high strain region may be increased by increasing the flexibility of the region.
- a structural element of a stent may include a flexible section embedded within a high strain region of the structural element.
- a high strain region e.g., section 70 in FIG. 2A
- the flexible section may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region.
- the abluminal and luminal surfaces of a stent tend to be in or substantially in a bending plane or surface of a structural element of a stent.
- the flexible section may have a greater flexibility than a majority of the structural element outside of the flexible section.
- the flexible section may be less brittle (or not brittle at all) and may have a lower modulus than a majority of the structural element outside of the flexible section.
- the flexible section may also have a T g at or below body temperature. Thus, a more flexible material in the flexible section may tend to be more resistant to the high strain in the high strain region during use of a stent.
- High strain regions may correspond to regions of structural elements that are configured to bend when stress is applied to a stent during use. Such stresses may arise from crimping, delivery, deployment, and beating of the heart. Examples of such high strain regions are sections 20 , 25 , and 30 in FIG. 1A .
- the flexible section may be selectively positioned to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
- One embodiment may include the flexible section selectively positioned proximate a center of a width of an abluminal surface and a luminal surface in the high strain region of the structural element.
- a neutral axis of a high strain region of a stent may be at or proximate a center of a width of an abluminal and luminal surface. Therefore, in some embodiments the flexible section may be selectively positioned proximate a neutral axis of the high strain region of the structural element.
- the flexible section In order to adequately increase the resistance to strain of the high strain region, it is advantageous for the flexible section go all the way through the high strain region from the abluminal to the luminal surface. However, in some embodiments, the section may go partially through the thickness of the high strain region, either from the abluminal or the luminal surface.
- a cross-section of the flexible section in a plane of the abluminal/luminal surface may be a variety of shapes, e.g., long and narrow; circular; oval; etc.
- the flexible section may be slot-shaped or long and narrow, and positioned along at least a portion of a length of the high strain region.
- the cross section of the flexible section can vary through the thickness of the stent.
- FIG. 6 depicts a portion 300 of a structural element that has a flexible section 305 in a high strain region 310 of portion 300 .
- Region 310 has a neutral axis 315 .
- Angle 320 is the angle between an arm 325 and an arm 330 of portion 300 .
- the flexible section may separate at least a portion of the high strain region into three sections: flexible section 305 , rigid section 335 , and rigid section 340 .
- the separation of a portion of the high strain region into three sections may facilitate, allow, and/or increase independent movement of arms 325 and 330 .
- the flexible section may also tend allow arms 325 and 330 to bend with greater flexibility.
- FIG. 7 depicts portion 300 of FIG. 6 when it is expanded.
- FIG. 8 depicts portion 300 when it is compressed.
- the area of flexible section 305 changes as portion 300 bends, i.e., changes as a function of angle 320 between arms 325 and 330 .
- the change in the area is due to the difference in stress-strain behavior of flexible section 305 and sections of portion 300 surrounding flexible section 305 , i.e., sections 335 and 340 , and the rest of the portion 300 .
- Flexible section 305 has a lower modulus and is less brittle than sections 335 and 340 and the rest of portion 300 .
- the width of the flexible section may be relatively constant along the length of the high strain region. Alternatively, it may be desirable for the width of the flexible section to vary along the length of the high strain region. As depicted in FIG. 6 , the width of flexible section 305 when portion 300 is unstressed is widest at a plane of bending symmetry 317 and decreases with distance from plane 317 .
- a flexible section along the length of the high strain region may be directly proportional to a magnitude of the strain along the high strain region when the structural element is under stress. Therefore, a flexible section may be widest at or proximate to the center of a bending portion of the high strain region and decrease in either direction along a length of the high strain region.
- a high strain region may have two or more flexible sections.
- the two or more flexible sections may be positioned at or proximate a center of a width of an abluminal surface and luminal surface of the structural element.
- the two or more flexible sections may be proximate a neutral axis of the high strain region of the structural element. Multiple cavities may allow reduction in strain in the high strain region with less reduction in strength of the structural element.
- the flexible sections may be the of similar shape and depth or vary in shape and/or depth.
- FIG. 9 depicts a portion 400 of a structural element that has flexible sections 415 , 420 , and 425 in a high strain region 410 of portion 400 that has a neutral axis 430 .
- a method of forming a flexible section in a structural element of a stent may include forming a cavity within a high strain region of a structural element.
- the cavity may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region.
- the cavity may be formed by laser cutting the cavity in the high strain region.
- FIG. 10 depicts a portion 300 of a structural element with a cavity 355 .
- FIG. 10 shows an interior surface 345 of section 335 and exterior surface 350 of section 340 .
- the method may further include forming a flexible section within all or substantially all of the cavity.
- the flexible section may be formed by depositing a polymer or a polymer-solvent mixture into the cavity.
- a polymer-solvent mixture may be deposited, for example, by dipping, spraying, or controlled deposition.
- a controlled deposition system can be used that applies various substances only to certain targeted portions of an implantable medical device such as a stent.
- a representative example of such a system, and a method of using the same, is described in U.S. Pat. No. 6,395,326 to Castro et al.
- a controlled deposition system can be capable of depositing a substance in or on an implantable medical device having a complex geometry, and otherwise apply the substance so that coating is limited to particular portions of the device.
- the system can have a dispenser and a holder that supports the medical substrate.
- the dispenser and/or holder can be capable of moving in very small intervals, for example, less than about 0.001 inch.
- the dispenser and/or holder can be capable of moving in the x-, y-, or z-direction, and be capable of rotating about a single point.
- the controlled deposition system can include a dispenser assembly.
- the dispenser assembly can be a simple device including a reservoir which holds a composition prior to delivery, and a nozzle having an orifice through which the composition is delivered.
- One exemplary type of a dispenser assembly can be an assembly that includes an ink-jet-type printhead.
- Another exemplary type of a dispenser assembly can be a microinjector capable of injecting small volumes ranging from about 2 to about 70 nL, such as NanoLiter 2000 available from World Precision Instruments or Pneumatic PicoPumps PV830 with Micropipette available from Cell Technology System. Such microinjection syringes may be employed in conjunction with a microscope of suitable design.
- a polymer-solvent mixture can also be selectively deposited by an electrostatic deposition process. Such a process can produce an electrically charged or ionized coating substance. The electric charge causes the coating substance to be differentially attracted to the device, thereby resulting in higher transfer efficiency. The electrically charged coating substance can be deposited into or onto selected regions of the device by causing different regions of the device to have different electrical potentials.
- selective deposition of an implantable medical device may be performed using photomasking techniques.
- Deposition and removal of a mask can be used to selectively deposit substances into or onto surfaces of substrates.
- Masking deposition is known to one having ordinary skill in the art.
- some embodiments may include enhancing adhesion between the flexible section and adjacent sections of the structural element to inhibit separation or delamination.
- One embodiment of improving adhesion may include allowing at least a portion of a flexible section to mix with at least a portion of adjacent sections.
- a polymeric material for the flexible section may be selected to be miscible with the polymeric material of adjacent sections within a particular temperature range.
- the temperature during or after deposition of polymer-solvent mixture into a cavity in a high strain region may be selected so that mixing of polymers occurs at and near an interface of the flexible section and adjacent sections.
- the temperature during or after deposition of polymer-solvent mixture into a cavity in a high strain region may be selected so that mixing of polymers occurs at and near an interface of the flexible section and adjacent sections.
- a structural element may be composed of a high modulus polymer such as poly(L-lactide), poly(D,L-lactide), or poly( ⁇ -caprolactone), mixtures thereof, or copolymers thereof.
- a flexible section may composed of flexible polymers such as poly(D,L-lactide)-polyethylene glycol-poly(D,L-lactide) triblock copolymer, 70/30 poly(L-lactide-co-trimethylene carbonate), or polyanhydrides.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A stent for treating a bodily lumen with a flexible section in a high strain region is disclosed. A flexible section may be selectively positioned to reduce an amount of strain in the high strain region when subjected to the applied stress during use to inhibit or prevent fracturing in the high strain region.
Description
- 1. Field of the Invention
- This invention relates to implantable medical devices, such as stents. In particular the invention relates to stents having structural elements with flexible or deformable sections that increase the crack resistance of the stent during use.
- 2. Description of the State of the Art
- This invention relates to radially expandable endoprostheses, which are adapted to be implanted in a bodily lumen. An “endoprosthesis” corresponds to an artificial device that is placed inside the body. A “lumen” refers to a cavity of a tubular organ such as a blood vessel.
- A stent is an example of such an endoprosthesis. Stents are generally cylindrically shaped devices, which function to hold open and sometimes expand a segment of a blood vessel or other anatomical lumen such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in blood vessels. “Stenosis” refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce body vessels and prevent restenosis following angioplasty in the vascular system. “Restenosis” refers to the reoccurrence of stenosis in a blood vessel or heart valve after it has been treated (as by balloon angioplasty, stenting, or valvuloplasty) with apparent success.
- The treatment of a diseased site or lesion with a stent involves both delivery and deployment of the stent. “Delivery” refers to introducing and transporting the stent through a bodily lumen to a region, such as a lesion, in a vessel that requires treatment. “Deployment” corresponds to the expanding of the stent within the lumen at the treatment region. Delivery and deployment of a stent are accomplished by positioning the stent about one end of a catheter, inserting the end of the catheter through the skin into a bodily lumen, advancing the catheter in the bodily lumen to a desired treatment location, expanding the stent at the treatment location, and removing the catheter from the lumen.
- In the case of a balloon expandable stent, the stent is mounted about a balloon disposed on the catheter. Mounting the stent typically involves compressing or crimping the stent onto the balloon. The stent is then expanded by inflating the balloon. The balloon may then be deflated and the catheter withdrawn. In the case of a self-expanding stent, the stent may be secured to the catheter via a retractable sheath or a sock. When the stent is in a desired bodily location, the sheath may be withdrawn which allows the stent to self-expand.
- The stent must be able to satisfy a number of mechanical requirements. First, the stent must be capable of withstanding the structural loads, namely radial compressive forces, imposed on the stent as it supports the walls of a vessel. Therefore, a stent must possess adequate radial strength. Radial strength, which is the ability of a stent to resist radial compressive forces, is due to strength and rigidity around a circumferential direction of the stent. Radial strength and rigidity, therefore, may be also be described as, hoop or circumferential strength and rigidity.
- Additionally, the stent should also be longitudinally flexible to allow it to be maneuvered through a tortuous vascular path and to enable it to conform to a deployment site that may not be linear or may be subject to flexure. The material from which the stent is constructed must allow the stent to undergo expansion. Once expanded, the stent must maintain its size and shape throughout its service life despite the various forces that may come to bear on it, including the cyclic loading induced by the beating heart. Finally, the stent must be biocompatible so as not to trigger any adverse vascular responses.
- The structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements or struts. The scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed so that the stent can be radially contracted (to allowed crimping) and radially expanded (to allow deployment). A conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other. Such movement typically results in substantial deformation of localized portions of the stent's structure.
- Stents have been made of many materials such as metals and polymers, including biodegradable polymeric materials. An advantage of stents fabricated from polymers is that they can be designed to have greater flexibility than metal stents. However, a potential problem with polymeric stents is that their struts may be susceptible to cracking during crimping and expansion especially for brittle polymers. The localized portions of the stent pattern subjected to substantial deformation tend to be the most vulnerable to failure.
- Therefore, it would be desirable reduce or eliminate the susceptibility of cracking in a polymeric stent, particularly in localized regions of high deformation. It is also desirable to maintain or increase their flexibility while improving crack resistance.
- The present invention is directed to embodiments of a stent having structural elements that may include a flexible or deformable section embedded within a high strain region of a structural element. The flexible section may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region. The flexible section may have a greater flexibility than a majority of the structural element outside of the flexible section. The high strain region may have a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use. The section may be selectively positioned to increase resistance to strain in the high strain region to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
- A further aspect of the invention is directed to embodiments of a method of forming a stent. The method may include forming a cavity within a high strain region of a structural element. The cavity may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region. The high strain region may include a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use. The method may further include forming a flexible section within all or substantially all of the cavity. The flexible section may have a greater flexibility than a majority of the structural element outside of the flexible section. The section may be selectively positioned to reduce an amount of strain in the high strain region to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
-
FIG. 1A depicts a stent. -
FIG. 1B depicts a three-dimensional view of a portion of a stent. -
FIG. 2A depicts a side view of a portion of a stent. -
FIG. 2B depicts a side view of an expanded portion of a stent. -
FIG. 2C depicts a side view of a compressed portion of a stent. -
FIG. 3 depicts an expanded view of curved portion of a stent. -
FIG. 4 depicts a side view of a portion of a stent. -
FIG. 5 depicts a side view of a portion of a stent. -
FIG. 6 depicts a side view of a portion of a stent with a flexible section. -
FIG. 7 depicts a side view of an expanded portion of a stent with a flexible section. -
FIG. 8 depicts a side view of a compressed portion of a stent with a flexible section. -
FIG. 9 depicts a side view of a portion of a stent with multiple flexible sections. -
FIG. 10 depicts a three-dimensional side view of a portion of a stent with a cavity. - For the purposes of the present invention, the following terms and definitions apply:
- The “glass transition temperature,” Tg, is the temperature at which the amorphous domains of a polymer change from a brittle vitreous state to a solid deformable or ductile state at atmospheric pressure. In other words, the Tg corresponds to the temperature where the onset of segmental motion in the chains of the polymer occurs. When an amorphous or semicrystalline polymer is exposed to an increasing temperature, the coefficient of expansion and the heat capacity of the polymer both increase as the temperature is raised, indicating increased molecular motion. As the temperature is raised the actual molecular volume in the sample remains constant, and so a higher coefficient of expansion points to an increase in free volume associated with the system and therefore increased freedom for the molecules to move. The increasing heat capacity corresponds to an increase in heat dissipation through movement. Tg of a given polymer can be dependent on the heating rate and can be influenced by the thermal history of the polymer. Furthermore, the chemical structure of the polymer heavily influences the glass transition by affecting mobility.
- “Stress” refers to force per unit area, as in the force acting through a small area within a plane. Stress can be divided into components, normal and parallel to the plane, called normal stress and shear stress, respectively. Tensile stress, for example, is a normal component of stress applied that leads to expansion (increase in length). In addition, compressive stress is a normal component of stress applied to materials resulting in their compaction (decrease in length). Stress may result in deformation of a material, which refers to change in length. “Expansion” or “compression” may be defined as the increase or decrease in length of a sample of material when the sample is subjected to stress.
- “Strain” refers to the amount of expansion or compression that occurs in a material at a given stress or load. Strain may be expressed as a fraction or percentage of the original length, i.e., the change in length divided by the original length. Strain, therefore, is positive for expansion and negative for compression.
- Furthermore, a property of a material that quantifies a degree of strain with applied stress is the modulus. “Modulus” may be defined as the ratio of a component of stress or force per unit area applied to a material divided by the strain along an axis of applied force that results from the applied force. For example, a material has both a tensile and a compressive modulus. A material with a relatively high modulus tends to be stiff or rigid. Conversely, a material with a relatively low modulus tends to be flexible. The modulus of a material depends on the molecular composition and structure, temperature of the material, and the strain rate or rate of deformation. For example, below its Tg, a polymer tends to be brittle with a high modulus. As the temperature of a polymer is increased from below to above its Tg, its modulus decreases.
- The “ultimate strength” or “strength” of a material refers to the maximum stress that a material will withstand prior to fracture. A material may have both a tensile and a compressive strength. The ultimate strength may be calculated from the maximum load applied during a test divided by the original cross-sectional area.
- The term “elastic deformation” refers to deformation of an object in which the applied stress is small enough so that the object moves towards its original dimensions or essentially its original dimensions once the stress is released. However, an elastically deformed polymer material may be prevented from returning to an undeformed state if the material is below the Tg of the polymer. Below Tg, energy barriers may inhibit or prevent molecular movement that allows deformation or bulk relaxation.
- “Elastic limit” refers to the maximum stress that a material will withstand without permanent deformation. The “yield point” is the stress at the elastic limit and the “ultimate strain” is the strain at the elastic limit. The term “plastic deformation” refers to permanent deformation that occurs in a material under stress after elastic limits have been exceeded.
- “Neutral axis” refers to a line or plane in a structural member subjected to a stress at which the strain is zero. For example, a beam in flexure due to stress (e.g., at a top face) has tension on one side (e.g., the bottom face) and compression on the other (e.g., the top face). The neutral axis lies between the two sides at a location or locations of zero strain. The neutral axis may correspond to a surface. For a linear, symmetric, homogeneous beam, the neutral axis is at the geometric centroid (center of mass) of the beam. However, the neutral axis for a curved beam does not coincide with the centroidal axis.
- The strain increases in either direction away from the neutral axis. The length and strain of material elements parallel to the centroidal axis depend on both the distance of a material element from that axis and the radius of curvature of the curved beam.
- In general, polymers can be biostable, bioabsorbable, biodegradable, or bioerodable. Biostable refers to polymers that are not biodegradable. The terms biodegradable, bioabsorbable, and bioerodable, as well as degraded, eroded, and absorbed, are used interchangeably and refer to polymers that are capable of being completely eroded or absorbed when exposed to bodily fluids such as blood and can be gradually resorbed, absorbed and/or eliminated by the body.
- A stent made from a biodegradable polymer is intended to remain in the body for a duration of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. After the process of degradation, erosion, absorption, and/or resorption has been completed, no portion of the biodegradable stent, or a biodegradable portion of the stent will remain. In some embodiments, very negligible traces or residue may be left behind. The duration is typically in the range of six to eighteen months.
- In addition, a medicated stent may be fabricated by coating the surface of a stent with a polymeric carrier. The coating may include a bioactive agent. A “bioactive agent” is a moiety that is mixed, blended, bonded or linked to a polymer coating, or to a polymer from which a stent is made, and provides a therapeutic effect, a prophylactic effect, both a therapeutic and a prophylactic effect, or other biologically active effect upon release from the stent.
- Representative examples of polymers that may be used to fabricate embodiments of implantable medical devices disclosed herein include, but are not limited to, poly(N-acetylglucosamine) (Chitin), Chitosan, poly(3-hydroxyvalerate), poly(lactide-co-glycolide), poly(3-hydroxybutyrate), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), poly(caprolactone), poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(trimethylene carbonate), polyester amide, poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon 66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides, polyethers, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose. Additional representative examples of polymers that may be especially well suited for use in fabricating embodiments of implantable medical devices disclosed herein include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(butyl methacrylate), poly(vinylidene fluoride-co-hexafluoropropene) (e.g., SOLEF 21508, available from Solvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride (otherwise known as KYNAR, available from ATOFINA Chemicals, Philadelphia, Pa.), ethylene-vinyl acetate copolymers, poly(vinyl acetate), styrene-isobutylene-styrene triblock copolymers, and polyethylene glycol.
- The term “implantable medical device” is intended to include, but is not limited to, balloon-expandable stents, self-expandable stents, stent-grafts, and vascular grafts. In general, implantable medical devices, such as stents, can have virtually any structural pattern that is compatible with a bodily lumen in which it is implanted. Typically, a stent is composed of a pattern or network of circumferential and longitudinally extending interconnecting structural elements or struts. In general, the struts are arranged in patterns, which are designed to contact the lumen walls of a vessel and to maintain vascular patency. A myriad of strut patterns are known in the art for achieving particular design goals. A few of the more important design characteristics of stents are radial or hoop strength, expansion ratio or coverage area, and longitudinal flexibility.
- Polymer tubes used for fabricating stents may be formed by various methods. These include, but are not limited to extrusion or injection molding. Conventionally extruded tubes tend to possess no or substantially no radial orientation or, equivalently, polymer chain alignment in the circumferential direction.
- A tube used for fabricating a stent may be cylindrical or substantially cylindrical in shape. In some embodiments, the diameter of the polymer tube prior to fabrication of an implantable medical device may be between about 0.2 mm and about 10 mm, or more narrowly, between about 1 mm and about 3 mm.
- In general, the scaffolding of conventional stents is designed so that the stent can be radially compressed (to allowed crimping) and radially expanded (to allow deployment). A conventional stent expands and contracts through movement of individual structural elements of a pattern with respect to each other.
- Medical devices are typically subjected to stress during use, both before and during treatment. “Use” includes manufacturing, assembling (e.g., crimping a stent on a balloon), delivery of a stent through a bodily lumen to a treatment site, and deployment of a stent at a treatment site. The scaffolding or substrate experiences stress that results in deformation or strain in the scaffolding. For example, during deployment, the scaffolding of a stent can be exposed to stress caused by the radial expansion of the stent body. In addition, the scaffolding may be exposed to stress when it is mounted on a catheter from crimping or compression of the stent. During delivery, a stent can be exposed to stress from the flexure of the stent body as it passes through tortuous pathways of a vessel. In addition, after deployment a stent is exposed to stress arising from changes in shape of a vessel induced by the beating of the heart.
- These stresses can cause the scaffolding to crack or fracture. Failure of the mechanical integrity of the stent while the stent is localized in a patient can lead to serious risks for a patient. For example, there is a risk of embolization caused by a piece of the polymeric scaffolding breaking off from the stent.
- As indicated above, selected regions of a stent may be subjected to relatively high stress and strain when the device is under an applied stress during use. Thus, such regions may have different mechanical requirements than regions that experience relatively low stress and strain.
- Generally, the stress and the strain in a stent are not uniformly distributed throughout its structure. Some regions may experience no or substantially no stress and strain, while other portions may experience relatively high stress and strain. As indicated above, certain localized portions of the stent's structure undergo substantial deformation. It is these regions that are the most susceptible to fracture and cracking. The susceptibility to cracking may be reduced by making such regions more resistant to strain.
- Unfortunately, many polymers used for stent scaffoldings, are relatively brittle or inelastic at biological conditions. This is particularly true for polymers with a Tg above a body temperature. In this case, the polymer in the stent never reaches its Tg, and therefore, the polymer remains relatively inelastic while in the body. Polymers, in general, and many polymers used in scaffoldings for devices tend to have a relatively high degree of inelasticity, and, hence have relatively low strength compared to a metal. Polymers can have an ultimate strain as low as 5% of plastic strain. In general, the ultimate strain for a polymer is highly dependent on material properties including percent crystallinity, orientation of polymer chains, and molecular weight. Therefore, polymer-based scaffoldings are highly susceptible to fracture at regions of a medical device subjected to relatively high stress and strain.
- However, it is desirable for certain regions of a device to be relatively stiff or inelastic (high modulus) and strong. Such regions may experience relatively low stress and strain during use, but act as support members that resist radial compressive forces imposed on a deployed stent. Additionally, as discussed above, longitudinal flexibility in a stent facilitates delivery of the stent to a treatment location. Therefore, it is desirable to have a stent that is resistant to cracking in localized regions of high deformation, sufficiently rigid to maintain the structural integrity of the sent, and longitudinally flexible during delivery.
-
FIG. 1A illustrates a three-dimensional view of aconventional stent 10 with a typical stent pattern. The stent may have a pattern that includes a number of interconnecting elements or struts 15. Variations of the structure of such patterns are virtually unlimited. As shown inFIG. 1A , the geometry or shape of stents vary throughout their structure. A pattern may include portions of struts that are straight or relatively straight, an example being asection 17. In addition, patterns may include struts that include curved or bent portions as in asection 20. Patterns may also include intersections of struts with curved or bent portions as in 25 and 30. As shown insections FIG. 1A , struts 15 ofstent 10 include luminal faces 35, abluminal faces 40, and side-wall faces 45. -
FIG. 1B depicts aportion 54 of a strut depicting alatitudinal axis 50 and alongitudinal axis 55 along a straight section ofportion 54.Portion 54 has an abluminal orluminal face 59 and asidewall face 57. Alongitudinal axis 51 on a curved section of a strut may be defined as a tangent to a curvature at a location on the curved section. A correspondinglatitudinal axis 56 is perpendicular tolongitudinal axis 51. In other embodiments, a latitudinal cross-section may include any number of faces or be a curved surface. - In some embodiments, a pattern of a stent such as that pictured in
FIG. 1A , may be formed from a tube by laser cutting the pattern of struts in the tube. The stent may also be formed by laser cutting a polymeric sheet, rolling the pattern into the shape of the cylindrical stent, and providing a longitudinal weld to form the stent. Other methods of forming stents are well known and include chemically etching a polymeric sheet and rolling and then welding it to form the stent. The stent may be formed by injection molding of a thermoplastic or reaction injection molding of a thermoset polymeric material. - As indicated above, crimping and expansion of a stent with a typical pattern, such as in
FIG. 1A , result in localized regions of the pattern having high deformation or strain that are susceptible to failure. The stent pattern depicted inFIG. 1A may be used to illustrate such localized regions. Some portions of a stent pattern may have no or relatively no strain, while others may have relatively high strain. Straight or substantially straight sections of struts such assection 17 ofstent 10 inFIG. 1A experience no or relatively no strain. These sections, however, do act as support members that maintain the structural integrity of the stent. On the other hand, 20, 25, and 30 may experience relatively high strain when the stent is expanded or crimped.sections - For example, FIGS. 2A-C depict partial planar side views of luminal or abluminal surfaces of a
portion 60 from a stent in a relaxed state (neither expanded or compressed) that includesstraight sections 65 and acurved section 70 with anangle 85. When a stent undergoes radial expansion, portions of struts bend resulting in an increase ofangle 85 betweenstraight sections 65, as shown inFIG. 2B . - A bending plane of
portion 60 corresponds to the plane through whichsections 65 sweep through as they bend. For example, the bending plane may correspond to the plane of the sheet of paper. Thus, the abluminal and luminal surfaces may be substantially parallel to the bending plane of the bending portions of structural elements such asportion 60. - FIGS. 2B-C depict
portion 60 in a plane of bending. Radial expansion of a stent causes substantially no strain instraight sections 65. However, the bending ofsection 60 causes relatively high stress and strain incurved section 70. As illustrated inFIG. 2B , when a stent is expanded aconcave portion 75 ofcurved section 70 experiences relatively high tensile stress and strain and aconvex portion 80 ofcurved section 70 experiences relatively high compressive stress and strain. As shown inFIG. 2C , when a stent is crimped,angle 85 decreases andconcave portion 75 experiences relatively high compressive strain andconvex portion 80 experiences relatively high tensile strain. -
FIG. 3 depicts an expanded view ofcurved section 70 with aneutral axis 90 indicated. As indicated above, the strain along the neutral axis is zero. For a strut that is symmetric along its longitudinal and latitudinal axis, the neutral axis may be a surface perpendicular to a plane of bending (i.e., perpendicular to the plane of the sheet of paper). Additionally, as in a curved beam, acentroidal axis 95 of a curved section of a strut, such assection 70, does not coincide with the neutral axis. Therefore, in a small, narrow region ofcurved section 70 alongneutral axis 90, there is zero or relatively low strain. - Furthermore, the strain in a structural element or beam increases with distance from the neutral axis. Therefore, the strain in
section 70 depends on distance from theneutral axis 90 and the change in curvature from an equilibrium or unstressed curvature ofsection 70. For instance, abending moment 100 that tends to straightensection 70, as inFIG. 2B , results in strain above and below the neutral axis. The magnitude of the strain as a function of the distance from the neutral axis at aplane 105 is illustrated byarrows 110 and 115. Aboveneutral axis 90, the strut is in compression with a compressive strain that increases with distance fromneutral axis 90, as shown by arrows 110. Belowneutral axis 90 the strut is in tension with a tensile strain that increases with distance fromneutral axis 90, as shown byarrows 115. Similarly, a bending moment that tends to increase the bend insection 70, as inFIG. 2C , will result in tension above the neutral axis and compression below the neutral axis. - In general, the greater the change in curvature of a curved portion of a strut due to an applied stress, the larger the magnitude of the strain at a given distance away from the neutral axis (See
120 and 125 inarrows FIG. 3 ). The maximum tensile and compressive strain occur the edges of a structural element. InFIG. 3 , the maximum tensile and compressive strain alongplane 105 is at 120 and 125, respectively. - Furthermore, the magnitude of the strain in a bending element or beam varies along the longitudinal axis of the element. The maximum strain tends to occur at a center of symmetry of the bending element. The strain tends to decrease along the longitudinal axis with distance going away from the center of symmetry of the bend. For example, if
plane 105 is a center of symmetry of bending, the strain decreases with distance away fromplane 105 along a longitudinal axis ofsection 70 at a fixed distance fromneutral axis 90. -
FIG. 4 depicts a partial planar side view of aportion 150 from a stent in an unstressed state that includescurved section 155,straight sections 160 at anangle 165, andstraight section 170. Radial expansion of the stent increasesangle 165 and crimpingdecreases angle 165. The stress and strain in 160 and 170 is relatively small. When a stent is expanded,straight sections section 155 has relatively high tensile stress and strain above aneutral axis 175 and relatively high compressive stress and strain belowneutral axis 175. Alternatively, when a stent is expanded,section 155 has relatively high tensile stress and strain belowneutral axis 175 and relatively high compressive stress and strain aboveneutral axis 175. -
FIG. 5 depicts a partial planar side view of aportion 200 from a stent in an unstressed state that includes acurved section 205, 225, 230, and 240.straight sections 225 and 230 are at anStraight sections angle 235 and 230 and 240 are at anstraight sections angle 250. Radial expansion of the stent increases 235 and 250 and crimpingangles 235 and 250. The stress and strain indecreases angles 225, 230, and 240 is relatively small. When a stent is expanded,straight sections section 205 has relatively high tensile stress and strain above aneutral axis 260 and relatively high compressive stress and strain belowneutral axis 260. Alternatively, when a stent is compressed,section 205 has relatively high tensile stress and strain belowneutral axis 260 and relatively high compressive stress and strain aboveneutral axis 260. - The description and analysis relating to stress and strain distribution in a medical device is not limited to the structures in FIGS. 2A-C, 3, and 4. Analysis of strain distribution in a device, or generally any structure, subjected to applied stress may be performed for a device or structure of virtually any geometry
- As indicated above, high strain regions of polymeric stents, such as
section 70 in FIGS. 2A-C,section 155 inFIG. 3 , andsection 205 inFIG. 4 , may be susceptible to cracking during crimping or expansion of a stent. In general, the resistance to strain of the high strain region may be increased by increasing the flexibility of the region. - Certain embodiments of a structural element of a stent may include a flexible section embedded within a high strain region of the structural element. As noted above, a high strain region (e.g.,
section 70 inFIG. 2A ) may have a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use. - In an embodiment, the flexible section may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region. Generally, the abluminal and luminal surfaces of a stent tend to be in or substantially in a bending plane or surface of a structural element of a stent.
- The flexible section may have a greater flexibility than a majority of the structural element outside of the flexible section. In particular, the flexible section may be less brittle (or not brittle at all) and may have a lower modulus than a majority of the structural element outside of the flexible section. The flexible section may also have a Tg at or below body temperature. Thus, a more flexible material in the flexible section may tend to be more resistant to the high strain in the high strain region during use of a stent.
- As indicated above, applied stresses during use such as crimping, delivery and deployment cause deformation or strain in the structural elements of a stent. High strain regions may correspond to regions of structural elements that are configured to bend when stress is applied to a stent during use. Such stresses may arise from crimping, delivery, deployment, and beating of the heart. Examples of such high strain regions are
20, 25, and 30 insections FIG. 1A . - In some embodiments, the flexible section may be selectively positioned to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use. One embodiment may include the flexible section selectively positioned proximate a center of a width of an abluminal surface and a luminal surface in the high strain region of the structural element. As indicated above, (See
FIG. 3 ) a neutral axis of a high strain region of a stent may be at or proximate a center of a width of an abluminal and luminal surface. Therefore, in some embodiments the flexible section may be selectively positioned proximate a neutral axis of the high strain region of the structural element. In order to adequately increase the resistance to strain of the high strain region, it is advantageous for the flexible section go all the way through the high strain region from the abluminal to the luminal surface. However, in some embodiments, the section may go partially through the thickness of the high strain region, either from the abluminal or the luminal surface. - A cross-section of the flexible section in a plane of the abluminal/luminal surface may be a variety of shapes, e.g., long and narrow; circular; oval; etc. In one embodiment, the flexible section may be slot-shaped or long and narrow, and positioned along at least a portion of a length of the high strain region. In some embodiments, the cross section of the flexible section can vary through the thickness of the stent.
-
FIG. 6 depicts aportion 300 of a structural element that has aflexible section 305 in ahigh strain region 310 ofportion 300.Region 310 has aneutral axis 315.Angle 320 is the angle between anarm 325 and anarm 330 ofportion 300. - The flexible section may separate at least a portion of the high strain region into three sections:
flexible section 305,rigid section 335, andrigid section 340. The separation of a portion of the high strain region into three sections may facilitate, allow, and/or increase independent movement of 325 and 330. The flexible section may also tend allowarms 325 and 330 to bend with greater flexibility.arms -
FIG. 7 depictsportion 300 ofFIG. 6 when it is expanded. Similarly,FIG. 8 depictsportion 300 when it is compressed. As illustrated inFIGS. 7 and 8 , it is expected that the area offlexible section 305 changes asportion 300 bends, i.e., changes as a function ofangle 320 between 325 and 330. The change in the area is due to the difference in stress-strain behavior ofarms flexible section 305 and sections ofportion 300 surroundingflexible section 305, i.e., 335 and 340, and the rest of thesections portion 300.Flexible section 305 has a lower modulus and is less brittle than 335 and 340 and the rest ofsections portion 300. - In some embodiments, the width of the flexible section may be relatively constant along the length of the high strain region. Alternatively, it may be desirable for the width of the flexible section to vary along the length of the high strain region. As depicted in
FIG. 6 , the width offlexible section 305 whenportion 300 is unstressed is widest at a plane of bendingsymmetry 317 and decreases with distance fromplane 317. - It may be advantageous for the width of the flexible section along the length of the high strain region to be directly proportional to a magnitude of the strain along the high strain region when the structural element is under stress. Therefore, a flexible section may be widest at or proximate to the center of a bending portion of the high strain region and decrease in either direction along a length of the high strain region.
- In certain embodiments, a high strain region may have two or more flexible sections. In one embodiment, the two or more flexible sections may be positioned at or proximate a center of a width of an abluminal surface and luminal surface of the structural element. The two or more flexible sections may be proximate a neutral axis of the high strain region of the structural element. Multiple cavities may allow reduction in strain in the high strain region with less reduction in strength of the structural element. The flexible sections may be the of similar shape and depth or vary in shape and/or depth.
- As an illustration,
FIG. 9 depicts aportion 400 of a structural element that has 415, 420, and 425 in aflexible sections high strain region 410 ofportion 400 that has aneutral axis 430. - In certain embodiments, a method of forming a flexible section in a structural element of a stent may include forming a cavity within a high strain region of a structural element. The cavity may extend through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region. For example, the cavity may be formed by laser cutting the cavity in the high strain region. As an illustration,
FIG. 10 depicts aportion 300 of a structural element with acavity 355.FIG. 10 shows aninterior surface 345 ofsection 335 andexterior surface 350 ofsection 340. - Additionally, the method may further include forming a flexible section within all or substantially all of the cavity. The flexible section may be formed by depositing a polymer or a polymer-solvent mixture into the cavity. A polymer-solvent mixture may be deposited, for example, by dipping, spraying, or controlled deposition.
- A controlled deposition system can be used that applies various substances only to certain targeted portions of an implantable medical device such as a stent. A representative example of such a system, and a method of using the same, is described in U.S. Pat. No. 6,395,326 to Castro et al. A controlled deposition system can be capable of depositing a substance in or on an implantable medical device having a complex geometry, and otherwise apply the substance so that coating is limited to particular portions of the device. The system can have a dispenser and a holder that supports the medical substrate. The dispenser and/or holder can be capable of moving in very small intervals, for example, less than about 0.001 inch. Furthermore, the dispenser and/or holder can be capable of moving in the x-, y-, or z-direction, and be capable of rotating about a single point.
- The controlled deposition system can include a dispenser assembly. The dispenser assembly can be a simple device including a reservoir which holds a composition prior to delivery, and a nozzle having an orifice through which the composition is delivered. One exemplary type of a dispenser assembly can be an assembly that includes an ink-jet-type printhead. Another exemplary type of a dispenser assembly can be a microinjector capable of injecting small volumes ranging from about 2 to about 70 nL, such as NanoLiter 2000 available from World Precision Instruments or Pneumatic PicoPumps PV830 with Micropipette available from Cell Technology System. Such microinjection syringes may be employed in conjunction with a microscope of suitable design.
- A polymer-solvent mixture can also be selectively deposited by an electrostatic deposition process. Such a process can produce an electrically charged or ionized coating substance. The electric charge causes the coating substance to be differentially attracted to the device, thereby resulting in higher transfer efficiency. The electrically charged coating substance can be deposited into or onto selected regions of the device by causing different regions of the device to have different electrical potentials.
- Furthermore, selective deposition of an implantable medical device may be performed using photomasking techniques. Deposition and removal of a mask can be used to selectively deposit substances into or onto surfaces of substrates. Masking deposition is known to one having ordinary skill in the art.
- Furthermore, some embodiments may include enhancing adhesion between the flexible section and adjacent sections of the structural element to inhibit separation or delamination. One embodiment of improving adhesion may include allowing at least a portion of a flexible section to mix with at least a portion of adjacent sections. For example, a polymeric material for the flexible section may be selected to be miscible with the polymeric material of adjacent sections within a particular temperature range.
- In an embodiment, the temperature during or after deposition of polymer-solvent mixture into a cavity in a high strain region may be selected so that mixing of polymers occurs at and near an interface of the flexible section and adjacent sections. As a result of the mixing of polymers in an interfacial region, there may be a gradual transition in composition, and hence, in mechanical and other properties normal to the interfacial region between layers. A gradual transition in properties in an interfacial region may inhibit or prevent separation or delamination of the flexible section from a structural element.
- Some embodiments of the present invention are illustrated by the following examples. The examples are being given by way of illustration only and not by way of limitation. The parameters are not to be construed to unduly limit the scope of the embodiments of the invention.
- A structural element may be composed of a high modulus polymer such as poly(L-lactide), poly(D,L-lactide), or poly(ε-caprolactone), mixtures thereof, or copolymers thereof. A flexible section may composed of flexible polymers such as poly(D,L-lactide)-polyethylene glycol-poly(D,L-lactide) triblock copolymer, 70/30 poly(L-lactide-co-trimethylene carbonate), or polyanhydrides.
- While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
Claims (18)
1. A structural element of a stent comprising:
a flexible section embedded within a high strain region of a structural element, the flexible section extending through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region, the flexible section comprising a greater flexibility than a majority of the structural element outside of the flexible section;
wherein the high strain region comprises a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use,
wherein the section is selectively positioned to increase resistance to strain in the high strain region to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
2. The stent of claim 1 , wherein the stent comprises a biostable polymer and/or a bioabsorbable polymer.
3. The stent of claim 1 , wherein the flexible section comprises a biostable polymer and/or a bioabsorbable polymer.
4. The stent of claim 1 , wherein the flexible section comprises a lower modulus than a majority of the structural element outside of the flexible section.
5. The stent of claim 1 , wherein the flexible section comprises a glass transition temperature at or below body temperature.
6. The stent of claim 1 , wherein the high strain region comprises a region of the stent configured to bend when the structural element is under an applied stress during use.
7. The stent of claim 1 , wherein the section is selectively positioned proximate a center of a width of a bending portion of the structural element.
8. The stent of claim 1 , wherein the section is selectively positioned proximate a neutral axis of a bending portion of the structural element.
9. The stent of claim 1 , wherein a cross-section of the section is slot-shaped and positioned along at least a portion of a length of the high strain region.
10. The stent of claim 1 , wherein a width of the flexible section varies along the length of the high strain region.
11. The stent of claim 1 , wherein a width of the section along the length is directly proportional to strain along a length of the high strain region when the structural element is under stress.
12. The stent of claim 1 , wherein a width of the section is widest at a center of a bending portion of the high strain region and decreases along a length of the high strain region.
13. A method of forming a stent comprising:
forming a cavity within a high strain region of a structural element, the cavity extending through the high strain region from an abluminal surface of the high strain region to a luminal surface of the high strain region, wherein the high strain region comprises a higher strain as compared to other regions of the structural element when the stent is subjected to an applied stress during use;
forming a flexible section within all or substantially all of the cavity, the flexible section comprising a greater flexibility than a majority of the structural element outside of the flexible section, wherein the section is selectively positioned to reduce an amount of strain in the high strain region to inhibit or prevent fracturing in the high strain region when subjected to the applied stress during use.
14. The method of claim 13 , wherein the stent comprises a biostable polymer and/or a bioabsorbable polymer.
15. The method of claim 13 , wherein the flexible section comprises a biostable polymer and/or a bioabsorbable polymer.
16. The method of claim 13 , wherein the flexible section comprises a lower modulus than a majority of the structural element outside of the flexible section.
17. The method of claim 13 , wherein the cavity is formed by laser cutting the high strain region.
18. The method of claim 13 , wherein the flexible section is formed by depositing a polymer-solvent mixture into the cavity.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/141,834 US20060271170A1 (en) | 2005-05-31 | 2005-05-31 | Stent with flexible sections in high strain regions |
| PCT/US2006/020333 WO2006130440A1 (en) | 2005-05-31 | 2006-05-25 | Stent with flexible sections in high strain regions |
| US12/247,164 US8894900B2 (en) | 2005-05-31 | 2008-10-07 | Stent with flexible sections in high strain regions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/141,834 US20060271170A1 (en) | 2005-05-31 | 2005-05-31 | Stent with flexible sections in high strain regions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/247,164 Division US8894900B2 (en) | 2005-05-31 | 2008-10-07 | Stent with flexible sections in high strain regions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20060271170A1 true US20060271170A1 (en) | 2006-11-30 |
Family
ID=36968883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/141,834 Abandoned US20060271170A1 (en) | 2005-05-31 | 2005-05-31 | Stent with flexible sections in high strain regions |
| US12/247,164 Expired - Fee Related US8894900B2 (en) | 2005-05-31 | 2008-10-07 | Stent with flexible sections in high strain regions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/247,164 Expired - Fee Related US8894900B2 (en) | 2005-05-31 | 2008-10-07 | Stent with flexible sections in high strain regions |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US20060271170A1 (en) |
| WO (1) | WO2006130440A1 (en) |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD568476S1 (en) | 2006-10-27 | 2008-05-06 | Orbusneich Medical, Inc. | Interlocking tubular stent structure |
| US20090149940A1 (en) * | 2007-12-05 | 2009-06-11 | Yunbing Wang | Bioabsorbable stent with radiopaque layer and method of fabrication |
| WO2009079553A1 (en) * | 2007-12-19 | 2009-06-25 | Ethicon, Inc. | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| USD597671S1 (en) | 2006-10-20 | 2009-08-04 | Orbusneich Medical, Inc. | Polymeric stent structure |
| US20110112626A1 (en) * | 2009-10-06 | 2011-05-12 | Arterial Remodeling Technologies, S.A. | Bioresorbable vascular implant having homogenously distributed stresses under a radial load |
| WO2011094621A1 (en) * | 2010-01-30 | 2011-08-04 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
| US20110190872A1 (en) * | 2010-01-30 | 2011-08-04 | Abbott Cardiovascular Systems Inc. | Crush Recoverable Polymer Scaffolds Having a Low Crossing Profile |
| JP2013517913A (en) * | 2010-01-30 | 2013-05-20 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | Compressible polymer scaffold |
| US9173973B2 (en) | 2006-07-20 | 2015-11-03 | G. Lawrence Thatcher | Bioabsorbable polymeric composition for a medical device |
| US9211205B2 (en) | 2006-10-20 | 2015-12-15 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
| US9259339B1 (en) * | 2014-08-15 | 2016-02-16 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9271853B2 (en) | 2012-10-01 | 2016-03-01 | Brigham Young University | Vascular stents and related methods |
| US9345602B2 (en) | 2010-09-23 | 2016-05-24 | Abbott Cardiovascular Systems Inc. | Processes for making crush recoverable polymer scaffolds |
| WO2016161098A1 (en) * | 2015-04-02 | 2016-10-06 | Boston Scientific Scimed, Inc. | Stent having added feature for strain relief and mitigation of crack propagation |
| US9480588B2 (en) | 2014-08-15 | 2016-11-01 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9498359B2 (en) | 2012-07-13 | 2016-11-22 | Abbott Cardiovascular Systems Inc. | Polymer scaffolds for peripheral vessels |
| US9566371B2 (en) | 2007-01-19 | 2017-02-14 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
| US9724864B2 (en) | 2006-10-20 | 2017-08-08 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device |
| US9730819B2 (en) | 2014-08-15 | 2017-08-15 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9855156B2 (en) | 2014-08-15 | 2018-01-02 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9943426B2 (en) | 2015-07-15 | 2018-04-17 | Elixir Medical Corporation | Uncaging stent |
| US20180256374A1 (en) * | 2015-09-10 | 2018-09-13 | Bentley Innomed Gmbh | Expandable vascular stent |
| US10307274B2 (en) | 2011-07-29 | 2019-06-04 | Abbott Cardiovascular Systems Inc. | Methods for uniform crimping and deployment of a polymer scaffold |
| US10918505B2 (en) | 2016-05-16 | 2021-02-16 | Elixir Medical Corporation | Uncaging stent |
| US20220370215A1 (en) * | 2021-05-20 | 2022-11-24 | Cook Medical Technologies Llc | Self expanding stent and method of loading same into a catheter |
| US20230000648A1 (en) * | 2021-05-20 | 2023-01-05 | Cook Medical Technologies Llc | Self expanding stents and methods |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8372332B2 (en) * | 2008-08-11 | 2013-02-12 | Abbott Cardiovascular Systems Inc. | Fabricating an implantable medical device from an amorphous or very low crystallinity polymer construct |
| US8765040B2 (en) | 2008-08-11 | 2014-07-01 | Abbott Cardiovascular Systems Inc. | Medical device fabrication process including strain induced crystallization with enhanced crystallization |
| US8114149B2 (en) * | 2009-10-20 | 2012-02-14 | Svelte Medical Systems, Inc. | Hybrid stent with helical connectors |
| US8496698B2 (en) | 2010-07-15 | 2013-07-30 | Abbott Cardiovascular Systems, Inc. | Endoprosthesis having improved strain distribution |
| US9610179B2 (en) | 2013-03-12 | 2017-04-04 | Cook Medical Technologies Llc | Atraumatic stent crowns |
| TWI554258B (en) * | 2014-05-27 | 2016-10-21 | 國立臺灣大學 | Intravascular stent with regio-selective properties and structures |
Citations (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US432711A (en) * | 1890-07-22 | Refrigerator | ||
| US3687135A (en) * | 1969-08-20 | 1972-08-29 | Genrikh Borisovich Stroganov | Magnesium-base alloy for use in bone surgery |
| US3839743A (en) * | 1972-04-21 | 1974-10-08 | A Schwarcz | Method for maintaining the normal integrity of blood |
| US3900632A (en) * | 1970-02-27 | 1975-08-19 | Kimberly Clark Co | Laminate of tissue and random laid continuous filament web |
| US4104410A (en) * | 1973-12-21 | 1978-08-01 | Malecki George J | Processing of green vegetables for color retention in canning |
| US4110497A (en) * | 1976-07-02 | 1978-08-29 | Snyder Manufacturing Co., Ltd. | Striped laminate and method and apparatus for making same |
| US4346028A (en) * | 1979-12-14 | 1982-08-24 | Monsanto Company | Asbestiform crystalline calcium sodium or lithium phosphate, preparation and compositions |
| US4596574A (en) * | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| US4599085A (en) * | 1979-07-11 | 1986-07-08 | Neodontics, Inc. | Bone implant member for prostheses and bone connecting elements and process for the production thereof |
| US4612009A (en) * | 1984-06-19 | 1986-09-16 | Ceskoslovenska Akademie Ved | Biodegradable implant and a method for preparation thereof |
| US4633873A (en) * | 1984-04-26 | 1987-01-06 | American Cyanamid Company | Surgical repair mesh |
| US4656083A (en) * | 1983-08-01 | 1987-04-07 | Washington Research Foundation | Plasma gas discharge treatment for improving the biocompatibility of biomaterials |
| US4718907A (en) * | 1985-06-20 | 1988-01-12 | Atrium Medical Corporation | Vascular prosthesis having fluorinated coating with varying F/C ratio |
| US4722335A (en) * | 1986-10-20 | 1988-02-02 | Vilasi Joseph A | Expandable endotracheal tube |
| US4723549A (en) * | 1986-09-18 | 1988-02-09 | Wholey Mark H | Method and apparatus for dilating blood vessels |
| US4732152A (en) * | 1984-12-05 | 1988-03-22 | Medinvent S.A. | Device for implantation and a method of implantation in a vessel using such device |
| US4768507A (en) * | 1986-02-24 | 1988-09-06 | Medinnovations, Inc. | Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis |
| US4776337A (en) * | 1985-11-07 | 1988-10-11 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4816339A (en) * | 1987-04-28 | 1989-03-28 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
| US4818559A (en) * | 1985-08-08 | 1989-04-04 | Sumitomo Chemical Company, Limited | Method for producing endosseous implants |
| US4850999A (en) * | 1980-05-24 | 1989-07-25 | Institute Fur Textil-Und Faserforschung Of Stuttgart | Flexible hollow organ |
| US4877030A (en) * | 1988-02-02 | 1989-10-31 | Andreas Beck | Device for the widening of blood vessels |
| US20030009214A1 (en) * | 1998-03-30 | 2003-01-09 | Shanley John F. | Medical device with beneficial agent delivery mechanism |
| US20030181972A1 (en) * | 2002-03-22 | 2003-09-25 | Scimed Life Systems, Inc. | MRI and x-ray compatible stent material |
| US6663664B1 (en) * | 2000-10-26 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Self-expanding stent with time variable radial force |
| US20040088041A1 (en) * | 1999-07-20 | 2004-05-06 | Stanford Ulf Harry | Expandable stent with array of relief cuts |
| US20040098117A1 (en) * | 2001-06-29 | 2004-05-20 | Hossainy Syed F.A. | Composite stent with regioselective material and a method of forming the same |
| US6758859B1 (en) * | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
| US20050273157A1 (en) * | 2004-06-08 | 2005-12-08 | Gregory Pinchasik | Stent having struts with reverse direction curvature |
| US20060025852A1 (en) * | 2004-08-02 | 2006-02-02 | Armstrong Joseph R | Bioabsorbable self-expanding endolumenal devices |
| US20060271161A1 (en) * | 2005-05-26 | 2006-11-30 | Boston Scientific Scimed, Inc. | Selective treatment of stent side branch petals |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922020A (en) * | 1996-08-02 | 1999-07-13 | Localmed, Inc. | Tubular prosthesis having improved expansion and imaging characteristics |
| US20020038146A1 (en) * | 1998-07-29 | 2002-03-28 | Ulf Harry | Expandable stent with relief cuts for carrying medicines and other materials |
| US6293967B1 (en) * | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
| US6805898B1 (en) * | 2000-09-28 | 2004-10-19 | Advanced Cardiovascular Systems, Inc. | Surface features of an implantable medical device |
| US7014654B2 (en) * | 2001-11-30 | 2006-03-21 | Scimed Life Systems, Inc. | Stent designed for the delivery of therapeutic substance or other agents |
| US7794494B2 (en) * | 2002-10-11 | 2010-09-14 | Boston Scientific Scimed, Inc. | Implantable medical devices |
-
2005
- 2005-05-31 US US11/141,834 patent/US20060271170A1/en not_active Abandoned
-
2006
- 2006-05-25 WO PCT/US2006/020333 patent/WO2006130440A1/en active Application Filing
-
2008
- 2008-10-07 US US12/247,164 patent/US8894900B2/en not_active Expired - Fee Related
Patent Citations (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US432711A (en) * | 1890-07-22 | Refrigerator | ||
| US3687135A (en) * | 1969-08-20 | 1972-08-29 | Genrikh Borisovich Stroganov | Magnesium-base alloy for use in bone surgery |
| US3900632A (en) * | 1970-02-27 | 1975-08-19 | Kimberly Clark Co | Laminate of tissue and random laid continuous filament web |
| US3839743A (en) * | 1972-04-21 | 1974-10-08 | A Schwarcz | Method for maintaining the normal integrity of blood |
| US4104410A (en) * | 1973-12-21 | 1978-08-01 | Malecki George J | Processing of green vegetables for color retention in canning |
| US4110497A (en) * | 1976-07-02 | 1978-08-29 | Snyder Manufacturing Co., Ltd. | Striped laminate and method and apparatus for making same |
| US4599085A (en) * | 1979-07-11 | 1986-07-08 | Neodontics, Inc. | Bone implant member for prostheses and bone connecting elements and process for the production thereof |
| US4346028A (en) * | 1979-12-14 | 1982-08-24 | Monsanto Company | Asbestiform crystalline calcium sodium or lithium phosphate, preparation and compositions |
| US4850999A (en) * | 1980-05-24 | 1989-07-25 | Institute Fur Textil-Und Faserforschung Of Stuttgart | Flexible hollow organ |
| US4656083A (en) * | 1983-08-01 | 1987-04-07 | Washington Research Foundation | Plasma gas discharge treatment for improving the biocompatibility of biomaterials |
| US4633873A (en) * | 1984-04-26 | 1987-01-06 | American Cyanamid Company | Surgical repair mesh |
| US4596574A (en) * | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| US4612009A (en) * | 1984-06-19 | 1986-09-16 | Ceskoslovenska Akademie Ved | Biodegradable implant and a method for preparation thereof |
| US4732152A (en) * | 1984-12-05 | 1988-03-22 | Medinvent S.A. | Device for implantation and a method of implantation in a vessel using such device |
| US4718907A (en) * | 1985-06-20 | 1988-01-12 | Atrium Medical Corporation | Vascular prosthesis having fluorinated coating with varying F/C ratio |
| US4818559A (en) * | 1985-08-08 | 1989-04-04 | Sumitomo Chemical Company, Limited | Method for producing endosseous implants |
| US4776337B1 (en) * | 1985-11-07 | 2000-12-05 | Cordis Corp | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US4776337A (en) * | 1985-11-07 | 1988-10-11 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4768507A (en) * | 1986-02-24 | 1988-09-06 | Medinnovations, Inc. | Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis |
| US4723549A (en) * | 1986-09-18 | 1988-02-09 | Wholey Mark H | Method and apparatus for dilating blood vessels |
| US4722335A (en) * | 1986-10-20 | 1988-02-02 | Vilasi Joseph A | Expandable endotracheal tube |
| US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4816339A (en) * | 1987-04-28 | 1989-03-28 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
| US4877030A (en) * | 1988-02-02 | 1989-10-31 | Andreas Beck | Device for the widening of blood vessels |
| US20030009214A1 (en) * | 1998-03-30 | 2003-01-09 | Shanley John F. | Medical device with beneficial agent delivery mechanism |
| US20040088041A1 (en) * | 1999-07-20 | 2004-05-06 | Stanford Ulf Harry | Expandable stent with array of relief cuts |
| US6663664B1 (en) * | 2000-10-26 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Self-expanding stent with time variable radial force |
| US6758859B1 (en) * | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
| US20040098117A1 (en) * | 2001-06-29 | 2004-05-20 | Hossainy Syed F.A. | Composite stent with regioselective material and a method of forming the same |
| US20030181972A1 (en) * | 2002-03-22 | 2003-09-25 | Scimed Life Systems, Inc. | MRI and x-ray compatible stent material |
| US20050273157A1 (en) * | 2004-06-08 | 2005-12-08 | Gregory Pinchasik | Stent having struts with reverse direction curvature |
| US20060025852A1 (en) * | 2004-08-02 | 2006-02-02 | Armstrong Joseph R | Bioabsorbable self-expanding endolumenal devices |
| US20060271161A1 (en) * | 2005-05-26 | 2006-11-30 | Boston Scientific Scimed, Inc. | Selective treatment of stent side branch petals |
Cited By (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9173973B2 (en) | 2006-07-20 | 2015-11-03 | G. Lawrence Thatcher | Bioabsorbable polymeric composition for a medical device |
| USD597671S1 (en) | 2006-10-20 | 2009-08-04 | Orbusneich Medical, Inc. | Polymeric stent structure |
| US9211205B2 (en) | 2006-10-20 | 2015-12-15 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
| US9724864B2 (en) | 2006-10-20 | 2017-08-08 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device |
| USD568476S1 (en) | 2006-10-27 | 2008-05-06 | Orbusneich Medical, Inc. | Interlocking tubular stent structure |
| US9566371B2 (en) | 2007-01-19 | 2017-02-14 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
| US9101698B2 (en) * | 2007-12-05 | 2015-08-11 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with radiopaque layer and method of fabrication |
| US20090149940A1 (en) * | 2007-12-05 | 2009-06-11 | Yunbing Wang | Bioabsorbable stent with radiopaque layer and method of fabrication |
| US7981149B2 (en) | 2007-12-19 | 2011-07-19 | Advanced Technologies And Regenerative Medicine, Llc | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| US7972373B2 (en) | 2007-12-19 | 2011-07-05 | Advanced Technologies And Regenerative Medicine, Llc | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| EP3001986A1 (en) * | 2007-12-19 | 2016-04-06 | Cordis Corporation | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| CN101951860A (en) * | 2007-12-19 | 2011-01-19 | 伊西康公司 | Have make in abutting connection with the sacculus of the interconnective simple stress concentration zones of strut is distensible can biological absorption support |
| US20100249905A1 (en) * | 2007-12-19 | 2010-09-30 | Contiliano Joseph H | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| WO2009079553A1 (en) * | 2007-12-19 | 2009-06-25 | Ethicon, Inc. | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| US9566177B2 (en) | 2009-10-06 | 2017-02-14 | Artertial Remodeling Technologies, S.A. | Bioresorbable vascular implant having homogenously distributed stresses under a radial load |
| US20110112626A1 (en) * | 2009-10-06 | 2011-05-12 | Arterial Remodeling Technologies, S.A. | Bioresorbable vascular implant having homogenously distributed stresses under a radial load |
| US8808353B2 (en) | 2010-01-30 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds having a low crossing profile |
| CN104739551A (en) * | 2010-01-30 | 2015-07-01 | 艾博特心血管系统有限公司 | Crush Recoverable Polymer Scaffolds |
| JP2015120002A (en) * | 2010-01-30 | 2015-07-02 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | Compression recoverable polymer scaffolds |
| CN104739553A (en) * | 2010-01-30 | 2015-07-01 | 艾博特心血管系统有限公司 | Crush Recoverable Polymer Scaffolds |
| US8568471B2 (en) | 2010-01-30 | 2013-10-29 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
| JP2013517913A (en) * | 2010-01-30 | 2013-05-20 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | Compressible polymer scaffold |
| CN102740806B (en) * | 2010-01-30 | 2015-12-16 | 艾博特心血管系统有限公司 | crush recoverable polymer scaffold |
| US9770351B2 (en) | 2010-01-30 | 2017-09-26 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
| US9907685B2 (en) | 2010-01-30 | 2018-03-06 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
| CN102740806A (en) * | 2010-01-30 | 2012-10-17 | 艾博特心血管系统有限公司 | crush recoverable polymer scaffold |
| US9763818B2 (en) | 2010-01-30 | 2017-09-19 | Abbott Cardiovascular Systems Inc. | Method of crimping stent on catheter delivery assembly |
| US9827119B2 (en) | 2010-01-30 | 2017-11-28 | Abbott Cardiovascular Systems Inc. | Polymer scaffolds having a low crossing profile |
| US11324614B2 (en) | 2010-01-30 | 2022-05-10 | Abbott Cardiovascular Systems Inc. | Balloon expanded polymer stent |
| US10123894B2 (en) | 2010-01-30 | 2018-11-13 | Abbott Cardiovascular Systems Inc. | Method of crimping stent on catheter delivery assembly |
| US20110190871A1 (en) * | 2010-01-30 | 2011-08-04 | Abbott Cardiovascular Systems Inc. | Crush Recoverable Polymer Scaffolds |
| US20110190872A1 (en) * | 2010-01-30 | 2011-08-04 | Abbott Cardiovascular Systems Inc. | Crush Recoverable Polymer Scaffolds Having a Low Crossing Profile |
| US9867728B2 (en) | 2010-01-30 | 2018-01-16 | Abbott Cardiovascular Systems Inc. | Method of making a stent |
| WO2011094621A1 (en) * | 2010-01-30 | 2011-08-04 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
| US9642730B2 (en) | 2010-09-23 | 2017-05-09 | Abbott Cardiovascular Systems Inc. | Processes for making crush recoverable polymer scaffolds |
| US9345602B2 (en) | 2010-09-23 | 2016-05-24 | Abbott Cardiovascular Systems Inc. | Processes for making crush recoverable polymer scaffolds |
| US10307274B2 (en) | 2011-07-29 | 2019-06-04 | Abbott Cardiovascular Systems Inc. | Methods for uniform crimping and deployment of a polymer scaffold |
| US9498359B2 (en) | 2012-07-13 | 2016-11-22 | Abbott Cardiovascular Systems Inc. | Polymer scaffolds for peripheral vessels |
| US9271853B2 (en) | 2012-10-01 | 2016-03-01 | Brigham Young University | Vascular stents and related methods |
| US9855156B2 (en) | 2014-08-15 | 2018-01-02 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9730819B2 (en) | 2014-08-15 | 2017-08-15 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9480588B2 (en) | 2014-08-15 | 2016-11-01 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9259339B1 (en) * | 2014-08-15 | 2016-02-16 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US20180360628A1 (en) * | 2014-08-15 | 2018-12-20 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| WO2016161098A1 (en) * | 2015-04-02 | 2016-10-06 | Boston Scientific Scimed, Inc. | Stent having added feature for strain relief and mitigation of crack propagation |
| US9877853B2 (en) | 2015-04-02 | 2018-01-30 | Boston Scientific Scimed, Inc. | Stent having added feature for strain relief and mitigation of crack propagation |
| US9943426B2 (en) | 2015-07-15 | 2018-04-17 | Elixir Medical Corporation | Uncaging stent |
| US10786376B2 (en) * | 2015-09-10 | 2020-09-29 | Bentley Innomed Gmbh | Expandable vascular stent |
| US20180256374A1 (en) * | 2015-09-10 | 2018-09-13 | Bentley Innomed Gmbh | Expandable vascular stent |
| US10271976B2 (en) | 2016-05-16 | 2019-04-30 | Elixir Medical Corporation | Uncaging stent |
| US10383750B1 (en) | 2016-05-16 | 2019-08-20 | Elixir Medical Corporation | Uncaging stent |
| US10786374B2 (en) | 2016-05-16 | 2020-09-29 | Elixir Medical Corporation | Uncaging stent |
| US10076431B2 (en) | 2016-05-16 | 2018-09-18 | Elixir Medical Corporation | Uncaging stent |
| US10918505B2 (en) | 2016-05-16 | 2021-02-16 | Elixir Medical Corporation | Uncaging stent |
| US11622872B2 (en) | 2016-05-16 | 2023-04-11 | Elixir Medical Corporation | Uncaging stent |
| US12011378B2 (en) | 2016-05-16 | 2024-06-18 | Elixir Medical Corporation | Uncaging stent |
| US20220370215A1 (en) * | 2021-05-20 | 2022-11-24 | Cook Medical Technologies Llc | Self expanding stent and method of loading same into a catheter |
| US20230000648A1 (en) * | 2021-05-20 | 2023-01-05 | Cook Medical Technologies Llc | Self expanding stents and methods |
| US11896507B2 (en) * | 2021-05-20 | 2024-02-13 | Cook Medical Technologies Llc | Self expanding stent and method of loading same into a catheter |
| US12263104B2 (en) * | 2021-05-20 | 2025-04-01 | Cook Medical Technologies Llc | Self expanding stents and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| US8894900B2 (en) | 2014-11-25 |
| US20090036972A1 (en) | 2009-02-05 |
| WO2006130440A1 (en) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8894900B2 (en) | Stent with flexible sections in high strain regions | |
| US9808362B2 (en) | Stent fabricated from polymer composite toughened by a dispersed phase | |
| US7476245B2 (en) | Polymeric stent patterns | |
| US8366762B2 (en) | Method of making a medical device with regioselective structure-property distribution | |
| US9833344B2 (en) | Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance | |
| US7875233B2 (en) | Method of fabricating a biaxially oriented implantable medical device | |
| US7291166B2 (en) | Polymeric stent patterns | |
| EP2134381B1 (en) | Implantable medical devices fabricated from block copolymers | |
| US20060224226A1 (en) | In-vivo radial orientation of a polymeric implantable medical device | |
| US8940037B2 (en) | Stent having circumferentially deformable struts | |
| US20140081372A1 (en) | Stent with retention protrusions formed during crimping | |
| US20090012598A1 (en) | Method of fabricating an implantable medical device by deformation of a tube or a sheet | |
| US8414638B2 (en) | Method for fabricating a polymer stent with break-away links for enhanced stent retenton | |
| US20110224778A1 (en) | Stent pattern for polymeric stents | |
| US8636811B2 (en) | Drug eluting rolled stent and stent delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GALE, DAVID;KLEINE, KLAUS;ABBATE, ANTHONY;AND OTHERS;REEL/FRAME:016642/0344;SIGNING DATES FROM 20050512 TO 20050516 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |